Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin plus S-1 versus docetaxel for second-line advanced driver-negative lung adenocarcinoma
ChiCTR1800014367Phase 2Not yet recruiting
- Sponsor
- Yinyi Biotech
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC) comparing Avastin + S-1 with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
bevacizumabtegafurdocetaxel
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800014367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014367.